MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, FHTX had $16,762K increase in cash & cash equivalents over the period. -$18,860K in free cash flow.

Cash Flow Overview

Change in Cash
$16,762K
Free Cash flow
-$18,860K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-52,619 -
Stock-based compensation expense
2,733 5,425
Depreciation and amortization expense
852 1,678
Impairment of long-lived assets
0 -
Noncash lease expense
696 2,967
Accretion of discount on marketable securities
356 1,264
Prepaid expenses and other current assets
-1,339 -1,989
Accounts payable
-110 -463
Accrued expenses and other liabilities
1,157 -388
Operating lease liabilities
-1,169 -4,633
Deferred revenue
-8,153 -13,509
Net cash used in operating activities
-18,860 -44,968
Purchases of property and equipment
0 50
Purchases of marketable securities
4,002 93,264
Proceeds from maturities of marketable securities
39,575 156,549
Net cash provided by (used in) investing activities
35,573 63,235
Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions
0 0
Payments of public offering costs
0 0
Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan
49 393
Net cash provided by financing activities
49 393
Net increase (decrease) in cash, cash equivalents and restricted cash
16,762 18,660
Cash and cash equivalents at beginning of period
57,162 -
Cash and cash equivalents at end of period
92,584 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics Inc. (FHTX)